Search Results - "Jurcic, J"

Genomic selection in forest trees comes to life: unraveling its potential in an advanced four-generation Eucalyptus grandis population by Duarte, Damián, Jurcic, Esteban J., Dutour, Joaquín, Villalba, Pamela V., Centurión, Carmelo, Grattapaglia, Dario, Cappa, Eduardo P.

“…Genomic Selection (GS) in tree breeding optimizes genetic gains by leveraging genomic data to enable early selection of seedlings without phenotypic data…”
Get full text

Breeding value predictive accuracy for scarcely recorded traits in a Eucalyptus grandis breeding population using genomic selection and data on predictor traits by Jurcic, Esteban J., Villalba, Pamela V., Dutour, Joaquín, Centurión, Carmelo, Munilla, Sebastián, Cappa, Eduardo P.

“…Genomic selection methods are particularly useful for traits that are difficult or expensive to measure. We investigated the impact of using predictor growth…”
Get full text

Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias by BURKE, J. M, CARON, P. C, JURCIC, J. G, PAPADOPOULOS, E. B, DIVGI, C. R, SGOUROS, G, PANAGEAS, K. S, FINN, R. D, LARSON, S. M, O'REILLY, R. J, SCHEINBERG, D. A

“…The monoclonal antibodies M195 and HuM195 target CD33, a glycoprotein found on myeloid leukemia cells. When labeled with iodine-131 ((131)I), these antibodies…”
Get full text

Radioimmunotherapy with alpha-emitting nuclides by McDevitt, M R, Sgouros, G, Finn, R D, Humm, J L, Jurcic, J G, Larson, S M, Scheinberg, D A

“…This review discusses the application of alpha particle-emitting radionuclides in targeted radioimmunotherapy. It will outline the production and chemistry of…”
Get full text

Molecular Remission Induction with Retinoic Acid and Anti-CD33 Monoclonal Antibody HuM195 in Acute Promyelocytic Leukemia by JURCIC, J. G, DEBLASIO, T, DUMONT, L, YAO, T.-J, SCHEINBERG, D. A

“…Despite achieving complete remission with retinoic acid (RA), most patients with acute promyelocytic leukemia (APL) have minimal residual disease detectable by…”
Get full text

Antibody therapy for residual disease in acute myelogenous leukemia by Jurcic, Joseph G.

“…The elimination of minimal residual disease remains one of the most promising applications of monoclonal antibody (mAb)-based therapies. An early study showed…”
Get full text

Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195 by FELDMAN, E, KALAYCIO, M, LEVITT, D, WEDEL, N, WEINER, G, FRANKEL, S, SCHULMAN, P, SCHWARTZBERG, L, JURCIC, J, VELEZ-GARCIA, E, SEITER, K, SCHEINBERG, D

“…HuM195 is a humanized, unconjugated, anti-CD33 monoclonal antibody. Fifty adult patients with relapsed or refractory AML were randomized to receive HuM195 at a…”
Get full text

Ab therapy of AML: native anti-CD33 Ab and drug conjugates by Jurcic, J.G., MD

“…MAb have become an important treatment modality in cancer therapy. Genetically engineered chimeric and humanized Ab have demonstrated activity against a…”
Get full text

A Phase I Trial of Humanized Monoclonal Antibody HuM195 (anti-CD33) with Low-Dose Interleukin 2 in Acute Myelogenous Leukemia by KOSSMAN, S. E, SCHEINBERG, D. A, JURCIC, J. G, JIMENEZ, J, CARON, P. C

“…HuM195 is a recombinant humanized IgG1 monoclonal antibody reactive with CD33, a M r 67,000 glycoprotein expressed on early myeloid progenitor cells and…”
Get full text

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER‐RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS by Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S. N., Tanaka, T. N., Zeidner, J. F., Garcia‐Manero, G., Jeyakumar, D., Gu, L., Tan, A., Chao, M., O'Hear, C., Lal, I., Vyas, P., Daver, N.

Get full text

Monoclonal antibody therapy of APL by Maslak, P G, Jurcic, J G, Scheinberg, D A

“…Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) for which a number of targeted therapies have been developed. The…”
Get more information

Single-step genomic prediction of Eucalyptus dunnii using different identity-by-descent and identity-by-state relationship matrices by Jurcic, Esteban J, Villalba, Pamela V, Pathauer, Pablo S, Palazzini, Dino A, Oberschelp, Gustavo P J, Harrand, Leonel, Garcia, Martín N, Aguirre, Natalia C, Acuña, Cintia V, Martínez, María C, Rivas, Juan G, Cisneros, Esteban F, López, Juan A, Poltri, Susana N Marcucci, Munilla, Sebastián, Cappa, Eduardo P

“…Genomic selection based on the single-step genomic best linear unbiased prediction (ssGBLUP) approach is becoming an important tool in forest tree breeding…”
Get full text

A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia : specific targeting without immunogenicity by CARON, P. C, JURCIC, J. G, LARSON, S. M, SCHEINBERG, D. A, SCOTT, A. M, FINN, R. D, DIVGI, C. R, GRAHAM, M. C, JUREIDINI, I. M, SGOUROS, G, TYSON, D, OLD, L. J

“…This trial studied the biodistribution, pharmacology, toxicity, immunogenicity, and biologic characteristics of a trace-labeled, anti-CD33, humanized…”
Get full text

Parametric Images of Antibody Pharmacokinetics in Bi213-HuM195 Therapy of Leukemia by Kolbert, Katherine S, Hamacher, Klaus A, Jurcic, Joseph G, Scheinberg, David A, Larson, Steven M, Sgouros, George

“…Kinetic analysis of gamma camera patient images can provide time-dependent information about antibody behavior. Current region-of-interest-based techniques for…”
Get full text

Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: long-term follow-up in acute promyelocytic leukemia by Jurcic, Joseph G., Nimer, Stephen D., Scheinberg, David A., DeBlasio, Tony, Warrell, Raymond P., Miller, Wilson H.

“…The t(15;17) translocation in acute promyelocytic leukemia (APL) yields a PML/RAR-α fusion messenger RNA species that can be detected by reverse…”
Get full text

Antibody therapy of acute myelogenous leukemia by Jurcic, J G

“…Monoclonal antibodies (mAbs) have become an important modality for cancer therapy. A genetically engineered, humanized anti-CD33 antibody HuM195 has…”
Get more information

Radioimmunotherapy of hematological cancer : problems and progress by JURCIC, J. G, SCHEINBERG, D. A

Get full text

Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias by Jurcic, J G, Caron, P C, Nikula, T K, Papadopoulos, E B, Finn, R D, Gansow, O A, Miller, Jr, W H, Geerlings, M W, Warrell, Jr, R P, Larson, S M

“…M195, a mouse monoclonal antibody reactive with the early myeloid antigen CD33, has been shown to target leukemia cells in patients and to reduce large…”
Get full text

Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195 by Jurcic, J G, Caron, P C, Miller, Jr, W H, Yao, T J, Maslak, P, Finn, R D, Larson, S M, Warrell, Jr, R P, Scheinberg, D A

“…Acute promyelocytic leukemia (APL) provides a model to examine the sequential use of selective oncogene product-targeted and lineage-targeted agents. All-trans…”
Get more information

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia by Sekeres, Mikkael A, Lancet, Jeffrey E, Wood, Brent L, Grove, Laurie E, Sandalic, Larissa, Sievers, Eric L, Jurcic, Joseph G

“…Improving outcomes in older adults with acute myeloid leukemia remains a formidable challenge. Lintuzumab (SGN-33; HuM195) is a humanized monoclonal antibody…”
Get full text